University of Miami, Miami, FL, USA.
Gynecol Oncol. 2012 Apr;125(1):256-62. doi: 10.1016/j.ygyno.2011.11.048. Epub 2011 Dec 7.
The use of adjuvant treatment(s) following initial hysterectomy and retroperitoneal nodal harvesting of patients with clinical stage I and II cervical carcinoma is (are) presently based on the pathological assessment of surgical specimens. This report sought to delineate further the clinical application of potential therapeutic interventions and associated follow-up investigations of this patient cohort.
The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journal and the application of a well-established consensus methodology (modified Delphi) to rate appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
From this process, 5 unique clinical variants were developed. These scenarios pertained to options of adjuvant radiation therapy and chemotherapy, methods of delivery of radiotherapy to optimize target volume coverage while simultaneously minimizing radiation exposure of adjacent healthy organs, and recommendations for patient follow-up care. Group members reached consensus of topic ratings in descending order of importance. A risk assessment breakdown was established to highlight the most likely indications for adjuvant treatment(s).
This assembly by the ACR of physicians involved in the management of patients with early stage cervical cancer was able to describe appropriateness criteria to aid other practitioners in selecting reasonable implementation of postoperative therapies and subsequent surveillance studies. These guidelines await further validation and refinement by both current and future prospectively randomized clinical studies regarding this patient population.
目前,对临床Ⅰ期和Ⅱ期宫颈癌患者进行初始子宫切除术和腹膜后淋巴结清扫后,辅助治疗的使用是基于手术标本的病理评估。本报告旨在进一步阐述该患者群体潜在治疗干预措施的临床应用及其相关随访研究。
美国放射学院(ACR)适宜性标准是针对特定临床情况的循证指南,每两年由多学科专家小组进行审查。指南的制定和审查包括对同行评议期刊的现有医学文献进行广泛分析,并应用成熟的共识方法(改良 Delphi 法)对小组进行成像和治疗程序的适宜性进行评分。在证据不足或不确定的情况下,可以使用专家意见来推荐成像或治疗。
从这个过程中,开发了 5 个独特的临床变体。这些情况涉及辅助放疗和化疗的选择、优化靶区覆盖范围同时最大限度减少相邻健康器官辐射暴露的放疗方法,以及患者随访护理的建议。小组成员就主题评分的重要性达成了共识。建立了风险评估细分,以突出辅助治疗最可能的适应症。
由参与早期宫颈癌患者管理的医生组成的 ACR 能够描述适宜性标准,以帮助其他从业者合理选择术后治疗和随后的随访研究。这些指南有待进一步验证和完善,需要当前和未来针对该患者群体的前瞻性随机临床试验来进行。